Targeting centrosome-mitotic kinases as a novel therapeutic approach against breast cancers in Hispanic/Latinas. Supplement1
Project Number3R01CA266046-03S1
Former Number5R01CA266046-02
Contact PI/Project LeaderSAAVEDRA, HAROLD I Other PIs
Awardee OrganizationPONCE SCHOOL OF MEDICINE
Description
Abstract Text
Project Summary
Non-Hispanic Black (NHB) and Hispanic/Latino (H/L) women with breast cancer have elevated mortality
rates relative to non-Hispanic White (NHW) women with breast cancer. This is, in part, due to the detection of
breast tumors at higher stages, and because of higher rates of triple-negative breast cancer (TNBC), a highly
aggressive breast cancer subtype associated with poor prognosis because of the lack of Estrogen (E),
Progesterone (P), and Her2 receptors. The prevalence of African ancestry in the genome of H/L from the
Caribbean (C-H/L) and NHB may contribute to elevated mortality rates because of higher rates of TNBC in
C-H/L and NHB relative to H/L and NHW women. Therefore, there is a need to identify novel biological
therapies specific to women of African heritage with TNBC. TTK and Nek2 are among sixteen kinases that
distinguish poor-prognosis basal/TNBC from better prognosis Luminal subtypes and can identify a
population of Luminal breast cancer patients with poor prognosis. The PI recently published that TTK and
Nek2 mRNAs are significantly overexpressed in breast cancers of NHB women. This is the first report that
finds dysregulated mitotic kinases in breast tumors of women from different races and ethnicities. The team
has also demonstrated that TTK and Nek2 can signal early stages of metastasis (the epithelial-to-
mesenchymal transition, or EMT, cell migration, and invasion through different mechanisms). Therefore, the
team has identified TTK and Nek2 as mitotic kinases that can be targeted in NHB and H/L women to suppress
metastatic TNBC. Given the preliminary results that the co-inhibition of mitotic kinases can suppress cell
migration and invasion to a larger extent than their single inhibition, and that these kinases can drive EMT
through distinct EMT transcription factors, the team proposes the hypothesis that the TTK and Nek2 mitotic
kinases cooperate to signal metastasis in TNBC by activating distinct EMT signal transduction pathways. The
overarching goal of this supplement, and what sets it apart from the parent proposal, is to identify at the
global genomic transcriptional level and the protein phosphorylation levels the mechanisms by which TTK
and Nek2 regulate global EMT pathways in TNBC cells from NHB women, and in TNBC PDX models from
C-H/L and NHB women. This will allow the team to identify the detailed mechanisms by which TTK and Nek2
support early metastasis by identifying the EMT master regulators (EMT transcription factors) whose
expression is modulated by the inactivation of TTK and Nek2 (Sub Aim 1.1), and how the phosphorylation
profile of proteins is involved in cell division, apoptosis, and EMT is affected upon co-inactivation of TTK and
Nek2 (Sub Aim 1.2).
Public Health Relevance Statement
Project Narrative
Identifying and targeting signaling pathways regulated by the mitotic kinases Nek2 and TTK, which are
overexpressed in non-Hispanic Black (NHB) and Hispanic/Latina (H/L) with breast cancer will reduce breast
cancer health disparities by preventing early metastatic progression in NHB, Caribbean-H/L, and other H/L
breast cancer patients. The investigators aim to elucidate these pathways using cell lines, and PDX models
of breast cancer established from NHB and H/L patients.
NIH Spending Category
No NIH Spending Category available.
Project Terms
AffectAfrican WomenAfrican ancestryApoptosisBiological Response Modifier TherapyBlack raceBreast Cancer CellBreast Cancer ModelBreast Cancer PatientCaribbean HispanicCaribbean regionCell LineCell divisionCentrosomeDeath RateDetectionEstrogensEthnic OriginGenetic TranscriptionGenomeGenomicsGoalsHispanicInvadedLatinaLatina PopulationLatinoMalignant Breast NeoplasmMammary NeoplasmsMessenger RNAMitoticNeoplasm MetastasisNot Hispanic or LatinoParentsPathway interactionsPatient-derived xenograft models of breast cancerPatientsPhosphorylationPhosphotransferasesPopulationPrevalenceProgesteronePrognosisProteinsPublishingRaceReportingResearch PersonnelSignal PathwaySignal TransductionSignal Transduction PathwayWhite WomenWomanaggressive breast cancerblack womencancer health disparitycancer subtypescell motilityepithelial to mesenchymal transitionnovelnovel therapeutic interventionoverexpressionpatient derived xenograft modelpreventreceptortranscription factortriple-negative invasive breast carcinoma
No Sub Projects information available for 3R01CA266046-03S1
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 3R01CA266046-03S1
Patents
No Patents information available for 3R01CA266046-03S1
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 3R01CA266046-03S1
Clinical Studies
No Clinical Studies information available for 3R01CA266046-03S1
News and More
Related News Releases
No news release information available for 3R01CA266046-03S1
History
No Historical information available for 3R01CA266046-03S1
Similar Projects
No Similar Projects information available for 3R01CA266046-03S1